Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128

Yogita K Adlakha and Neeru Saini*

Abstract

MicroRNAs, the non-coding single-stranded RNA of 19–25 nucleotides are emerging as robust players of gene regulation. Plethora of evidences support that the ability of microRNAs to regulate several genes of a pathway or even multiple cross talking pathways have significant impact on a complex regulatory network and ultimately the physiological processes and diseases. Brain being a complex organ with several cell types, expresses more distinct miRNAs than any other tissues. This review aims to discuss about the microRNAs in brain development, function and their dysfunction in brain tumors. We also provide a comprehensive summary of targets of brain specific and brain enriched miRNAs that contribute to the diversity and plasticity of the brain. In particular, we uncover recent findings on miRNA-128, a brain-enriched microRNA that is induced during neuronal differentiation and whose aberrant expression has been reported in several cancers. This review describes the wide spectrum of targets of miRNA-128 that have been identified till date with potential roles in apoptosis, angiogenesis, proliferation, cholesterol metabolism, self renewal, invasion and cancer progression and how this knowledge might be exploited for the development of future miRNA-128 based therapies for the treatment of cancer as well as metabolic diseases.

Keywords: miRNA, miRNA-128, Brain, Cancer, Apoptosis, Cholesterol

Introduction

MicroRNAs are small non-coding RNAs of 19–25 nucleotides in length and are known to regulate several protein-coding genes both in plants and animals. The first miRNA, lin-4 that controlled developmental timing in Caenorhabditis elegans was identified by two different groups in 1993 [1,2]. Later, let-7 miRNAs were found to control the timing of fate specification of neuronal and hypodermal cells during larval development [3-5]. Subsequently, numerous miRNAs have been implicated in a variety of cellular processes including differentiation, apoptosis, cell proliferation, embryonic development, stem cell renewal, stress response and metabolism [6-11]. Their profound impact on the regulation of numerous cellular processes clearly suggests that any aberration in miRNA biogenesis pathway or its regulation contributes to several human diseases such as cancer [12-14], cardiovascular diseases [15], schizophrenia [16], psoriasis [17], diabetes [18], chronic hepatitis [19], AIDS [20], and obesity [21].

MicroRNAs (miRNAs) interfere with target gene expression by binding to the 3′ UTRs of their target mRNAs and act primarily at the level of translation. Complete complementarity between miRNA and 3′ UTR of its target leads to the degradation of mRNA targets as shown in plants whereas partial complementarity leads to inhibition of translation as seen in mammals [22-24]. Literature reveals that a single miRNA can target several mRNAs together, and a single mRNA can be targeted by different miRNAs in a concerted manner. Large number of microRNAs and the capacity of each miRNA to target several transcripts suggest a complex regulatory network to fine tune the gene expression and a mechanism by which they are thought to regulate various processes during health and disease [25].

The advancement of high-throughput sequencing techniques has led to the rapid growth in the number of annotated miRNA. The most recent miRBase Sequence Database, Release 20 (http://www.mirbase.org/), harbours...
24521 entries representing hairpin precursor miRNAs and expressing 30424 mature miRNA products in 193 species [26]. The sequences of most miRNAs are conserved across large evolutionary distances, suggesting a conserved role in regulation of various physiological processes [27].

The diversity and gene-regulatory capacity of miRNAs is particularly valuable in the brain, where persistent flow of information and functional specialization of neurons requires constant neuronal adaptation to environmental cues [28]. The brain expresses more distinct and largest number of miRNAs than any other tissue in vertebrates as it has wide variety of cell types, neuronal and nonneuronal (for e.g. astrocytes) [29]. In this review, we summarize present knowledge on the microRNA expression and functions in the brain and their potential involvement in relation to brain tumors. Herein, we also give an overview of the functions and targets of brain-enriched and brain-specific miRNAs before delving into specific example of miRNA-128, the most abundant brain-enriched miRNA. We believe that the understanding of the impact of microRNA-128 on regulation of proliferation, apoptosis and metabolic processes is still at its dawn and needs further research for the development of future miRNA-based therapies for the treatment of metabolic diseases and cancer.

**MicroRNA biogenesis and mechanism of action**

Approximately, 50% of the mammalian miRNAs have found their location in introns or exons of protein-coding genes or introns of long non-coding RNAs [30,31]. Their expression is either derived by independent transcriptional units or by protein-coding gene transcriptional units [32]. As shown in Figure 1, miRNAs are transcribed from genomic DNA by RNA polymerase II or III into long, primary transcripts (pri-miRNAs) just like other protein coding genes. These pri-miRNAs are several kilobases in length and usually possess a 5′ CAP and a 3′ poly (A) tail. These pri-miRNAs are processed by a microprocessor complex which consists of a ribonuclease III (RNase III) named Drosha, a RNA-binding protein DiGeorge syndrome critical region 8 (DGCR8/Pasha) and a variety of co-factors [DEAD box helicases p68 and p72 and the heterogeneous nuclear ribonucleoproteins (hnRNPs)] which are thought to promote the specificity and/or activity of Drosha cleavage [32-35]. Drosha processing occurs co-transcriptionally in most mammalian miRNAs i.e. before splicing of host RNA (canonical pathway). However, Drosha pathway can be evaded by miTRons (a subset of intronic miRNAs) and are made by splicing and debranching of short hairpin introns [36,37]. The product of Drosha cleavage is a 70–100 nucleotide hairpin-shaped precursor referred to as pre-miRNA. These pre-miRNAs are exported to the cytoplasm by Ran-GTP and Exportin-5 dependent mechanisms [38]. In cytoplasm, these pre-miRNAs are excised by the RNase III enzyme Dicer into a double-stranded RNA of ~22 nucleotides in length, referred to as the miRNA:miRNA* duplex or by Ago2, an Argonaute protein that is part of the RISC complex and aligns the miRNA and messenger RNA [39,40]. The criteria for binding and cleavage by Ago2 after the 30th nucleotide are short stem and spanning of the loop by miRNA sequence. The duplex produced by either Dicer or Ago2 is loaded onto an Argonaute protein where one strand, i.e. guide strand, complementary to the target mRNA, is selected and subsequently forms the miRNA effector as part of a miRISC (miRNA-induced silencing complex), while the remaining strand (the “passenger strand”) is released and degraded [41]. Similar to Drosha and Dicer assisting proteins, the formation of the miRISC and the execution of its activity involve many additional factors [42]. The two key factors involved in the assembly and function of miRISCs are Argonaute (AGO) proteins, which directly interact with miRNAs, and glycine-tryptophan protein of 182 kDa (GW182), which act as downstream effectors in the repression. miRNA then guides the miRISC to recognize the partially complementary binding sites located in the 3′ UTR of their target mRNAs.

The perfect binding between seed region (5′ 2–8 nucleotides 3′) of mature miRNA and 3′ UTR of their target by Watson-Crick base-pairing is considered to be the major determinant in blocking the target mRNA either by translational repression or mRNA degradation [43]. However other 3′- supplementary and 3′- compensatory binding sites in miRNA sequence also play a significant role during interactions [24]. Although miRNA binding sites are most common in 3′ UTRs of mRNAs, yet there are some reports of miRNA interaction within the 5′ UTR, mRNA coding region and intron-exon junctions [44,45]. The detailed mechanisms underlying the inhibition of protein synthesis by miRNAs are not well understood, but literature suggests sequestration of mRNA into P bodies from ribosomes, blockage of translational initiation, translational repression or target deadenylation coupled to transcript degradation [23,46]. However, it is now believed that miRNA regulate gene expression in majority of cases by mRNA decay rather than translational repression [47]. Epigenetic modifications and transcription factors also play a decent role in the regulation of miRNA function. Recent reports also depict the role of pseudogenes as miRNA sequestering sponges or decoys in the regulation of miRNA function [48,49].

**MicroRNAs in brain development and function**

The brain is a complex organ, with various types of cells (neurons and non-neurons) that form an intricate communication network. Literature reveals that 70% of known miRNAs are expressed in the brain [50]. Surprisingly, only a handful of microRNAs are expressed in a brain specific or brain-enriched manner [51]. Since these miRNAs are dynamically regulated during brain development, have
different targets and perform different functions in brain, herein we provide a comprehensive list of the recent validated roles of brain-enriched and brain-specific microRNAs along with their targets in brain in Tables 1 and 2. The increasing variety of miRNAs being identified in the brain suggests a sheer connection between the biogenesis, dynamics of action and regulatory potential of miRNAs and the complexity of the brain. Numerous studies on depletion of the Dicer gene in the nervous system of animal models further demonstrate that microRNAs play essential roles in controlling neuronal proliferation, migration and precursor fates [167-171] and serve important roles in development and function in the brain [172,173]. Stark et al. in their study, have illustrated the contribution of defects in miRNA biogenesis to brain abnormalities in Dicer deficient mice and mouse model of schizophrenia [174].

An expression profiling study by Sempere et al. showed a group of 17 miRNAs were expressed in mouse and human brain (miR-7, -9, -9*, -124a, -124b, -125a, -125b, -128, -132, -135, -137, -139, -153, -149, -183, -190, -219). All these miRNAs have been found to regulate neuronal differentiation, maturation, and/or survival in mouse and human. Conservation of these miRNAs between mouse and human suggests that they may play a conserved role in the establishment and/or maintenance of a cell or tissue type of brain [52,55,106,175]. Specific expression of miR-9 and miR-132 is restricted to hippocampus and medial frontal gyrus [176] whereas miR-124 and miR-128 are unique for neurons and miR-23, miR-26 and miR-29 are specifically expressed in astrocytes [177]. In addition miR-195 displays a moderate to low expression level in the mammalian embryonic brain, with the highest level at the preadult brain developmental stage [178].

Studies have further shown that miR-9 expression is necessary for neurogenesis in cultured stem cells and miR-132 plays a role in neurite extension and neurogenesis [52,179]. MiR-132 is also linked to BDNF (a member of the nerve growth factor family that is necessary for survival of striatal neurons in the brain) and MeCP2 (methyl-CpG DNA binding protein that plays an...
essential role in mammalian development) by a negative feedback loop [81]. Interestingly, miR-124 when overexpressed in non-neuronal HeLa cells shifts the gene expression profile from an immature cervix cell into a neuronal phenotype, suggesting that miR-124 downregulates mRNAs directing cells into a non-neuronal phenotype [180]. Recently, it has been observed that MiR-124 targets REST, BTBP and Sox9, all proteins have been known to antagonize the formation of neuronal cells during development [106,113,114]. Similar to miR-124, miRNA-128 is induced during brain development and in differentiating neuronal cells; leading to repressed NMD (Nonsense-mediated decay) and the consequent upregulation of batteries of mRNAs encoding proteins important for neuron differentiation and function [56]. MiR-23 is implicated in neural specification while miR-26 is required during neuronal cell differentiation. Report by Kole et al. showed that miR-29b is markedly induced during neuronal maturation and functions as an inhibitor of neuronal apoptosis [181]. Apart from development, aberrant microRNA expression has been discovered in human CNS (central nervous system) diseases including brain tumors in the past decade.

### Table 1 Comprehensive list of brain enriched microRNAs and their targets and functions related to brain

| Brain enriched miRNAs | Target | Function | Ref |
|------------------------|--------|----------|-----|
| miR-9* | SOX2 | Induces neuronal differentiation, affects both proliferation and differentiation | [52-54] |
| miRNA-128 | Reelin, DCX, SUZ12, neurofibromin 1, BMI1, RTK, EGFR, PDGFRα/β, MLN51, NTRK3, WEE1, Bax, E2F3a, SNAP25 | Synaptogenesis; reduces neuroblastoma cell motility and invasiveness; suppressor of PRC activity; renders glioma stemlike cells less radioresistant; suppressor of the colony formation ability and invasiveness of pituitary tumor cells; suppressor of growth and mediates differentiation; regulates Nonsense-mediated decay; regulates apoptosis; inhibits proliferation and self-renewal. | [55-68] |
| miR-7 | KLF4, α-synuclein, Sep21b, EGFR, IRS-2 | Suppresses brain metastasis, control neurite outgrowth, protects against oxidative stress, potential tumor suppressor; decreases viability and invasiveness of primary glioblastoma | [65,69-74] |
| miR-125 a-b | NR2A, SMG1, SMAD4 | regulates synaptic plasticity; regulates Nonsense-mediated decay. | [52,75-77] |
| miR-23 | laminB1, X-linked inhibitor of apoptosis (XIAP) | regulates oligodendrocyte development and myelination, regulates cerebral ischemia and neural specification | [78,79] |
| miR-132 | PTP2B, AChE, Foxp2, Sirt1, MeCP2, ATAT2, DSYSL3, STAT4; p250RhoGAP, Mecp2, Ep300, Jarid1a, Btg2, Paip2a, For more targets view [80] | Regulates progressive supranuclear palsy, regulator of the brain-to-body resolution of inflammation, contribute to neurodevelopmental and neuromorphological pathologies, neuronal cell development, regulate synaptic plasticity, neuronal maturation, regulates basal and activity-induced neurite outgrowth, regulates recognition memory and synaptic plasticity, regulates Circadian Clock. | [52,80-93] |
| miR-137 | CDK6, MindBomb-1, CSM-D1, C10orf26, CACNA1C, TCF4, ZNF804A, neurofibromin 1, CSE1L, Cox-2, LSD1, MITF, EZH2, KLF4, SPTLC1, For more targets view [94] | Inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells, neuronal maturation, regulates differentiation of neural stem cells, suppress growth and invasion of oligodendroglioma and glioma cells, | [52,67,94-102] |
| miR-139 | Mcl-1, C-X-C chemokine receptor type 4 (CXCR4), FoxO1, CGP1, Bcl2 | Suppressor of the proliferation and enhances drug induced apoptosis, Reduced invasion and metastasis, Regulates Transcriptional activity. | [52,88,103-105] |

### Dysfunction of microRNAs in brain tumors

Gliomas are the primary brain tumors that are made up of glial cells which provide important structural support for the nerve cells in the brain. Malignant gliomas are the most common and lethal tumors arising in the central nervous system and are classified by the World Health Organization (WHO) into four different grades based on malignancy (I, II, III, IV) [182,183]. Grade IV glioblastoma multiforme (GBM) is the most common lethal primary brain tumor in adults that is characterized by aggressive vascular proliferation, invasiveness, stem cell-like behaviour and chemoresistance to new and traditional therapies [183]. Accumulating evidences indicate the presence of different miRNAs with pro-oncogenic and anti-oncogenic properties in glioblastomas. Koshkin et al. recently observed gradual increase in miR-21 and miR-23a levels in all tumor grades and significant decrease of miR-7 and miR-137 depending on the glioma grade [184]. Further,
miR-210 has been found to be highly expressed in human gliomas and confers a poor prognosis in glioma patients [185]. MicroRNA-206 has been found to be a tumor suppressor in human malignant cancers. Low miR-206 expression is associated with poor overall survival in patients with malignant astrocytomas, hence it could become a valuable marker of astrocytoma progression [186]. Apart from these, several independent studies observed that the expressions of miR-16, miR-503, miR-203, miR-34c-3p, miR-34c-5p, miR-106a, Let-7a, miR-218, miR-223, miR-34a, miR-329, miR-145, miR-124, miR-137, miR-138, miR-219-5p, miR-495, miR-383, miR-200b, miR-134, miR-153, miR-195, miR-143, miR-107, miR-326, miR-204 and miR-214 were significantly reduced in high WHO grade glioma tissues relative to low WHO grade glioma tissues and normal brain tissues [115,135,152,160,187-208]. The expression of most of these miRNAs decreases with increasing degrees of malignancy. The low expression of Let-7a was correlated with poor prognosis of primary glioblastoma patients [192]. Further, miR-708 and miR-17~92 cluster were downregulated in GBM tumor cell lines whereas three miR-17~92 cluster miRNAs (miR-2, -19a and -20) were upregulated in human medulloblastoma with aberrantly activated sonic hedgehog (SHH) signaling pathway [209-211]. Another group by Skalsky and Ciafre et al. in their cluster analysis further revealed that miR-139, miR-95 and miR-873 were downregulated specifically in glioblastomas and miR-137 and miR-181a/b were down-regulated in gliomas whereas miR-7, miR-124 and miRNA-128 were down-regulated in both [212,213]. Interestingly, miRNA-128 and miR-124 are not
only down regulated in gliomas but also other brain cancers including medulloblastomas and neuroblastomas [212,214]. Li et al. reported that decreased miR-146b-5p expression was strongly correlated with chromosome 10q loss in gliomas, especially glioblastomas [215]. The significance of the sequence of miRNA can be illustrated by the example of miR-23 in brain. The expression of miRNA-23b was gradually downregulated with the malignancy of glioma whereas miR-23a was upregulated in malignant glioma tissues [216,217]. Further, miR-328, miR-106b-5p, miR-155, miR-650, miR-92b, miR-30a-5p, miR-10b, miR-372, miR-183, miR-486 and miR-17 were found to be upregulated in invading glioma cells in vivo and glioma tissues respectively as revealed by miRNA expression profiling of microdissected human tumor biopsy specimens [218-228]. MiR-650 expression can be used as a significant prognostic indicator in glioma. MiR-19a, -19b and miR-9 have been found to be overexpressed in glioma cell lines and astrocytic glioma tissues, and their expression level is positively correlated with tumor grades [107,229]. Several studies showed that miR-21 and miR-10b are upregulated in glioblastomas and has recently been shown to be a significant contributor for tumor growth in vivo [230,231]. Wu et al. have recently documented that overall patient survival for those with low miR-21 expression was significantly longer than those patients with high miR-21 expression [232]. Further, miRNA-21, 221, 222, 181b, 181c, and 128a were found to be significantly deregulated in GBM tissues by Slaby et al. and Zhou et al. It was also observed that miRNA-181b and 181c were the most down regulated miRNAs in patients who responded to radiation therapy (RT) and temozolomide (TMZ) and hence could serve as predictors for RT/TMZ response. Several differentially expressed miRNAs such as miR-124, miR-21, -128, -181, -221 and -222 could serve as potential biomarkers in GBM in general since they play common role in the etiology of malignant brain tumors [233,234].

**Role of pro-neural miRNA-128 in brain related disorders**

MiRNA-128 is transcribed by two distinct genes, miRNA-128-1 and miRNA-128-2 in two primary transcripts, which are processed into an identical mature miRNA sequence. MiRNA-128-1 and miRNA-128-2 are both present in the intronic regions of two genes on two different chromosomes. MiRNA-128-1 is embedded in the R3HDM1 (R3H domain containing 1) gene on chromosome 2q21.3 and miRNA-128-2 is in the ARPP21 (cyclic AMP-regulated phosphoprotein, 21 kDa) on chromosome 3p22.3 [57]. Evidences in the literature reveal that miRNA-128 has tissue specific and developmental specific expression patterns. Apart from brain, miRNA-128 has also been found in the skeletal muscle and thymus and is highly expressed during neuronal differentiation. Down regulation of miRNA-128 has been reported in several brain cancers for example-glioblastoma [213] and medulloblastoma [235]. Allelic loss in chromosome 3p, where miRNA-128-2 is present, has also been associated with the most aggressive forms of neuroblastoma [213].

Cui et al. demonstrated that the down-regulation of miRNA-128 inversely correlates with tumor grade. They also observed that the decrease of miRNA-128 is coupled with significant increase in the expression of Bmi-1, the transcription factor E2F-3a and angiopoietin-related growth factor 5 (ARPP5; ANGPTL6). Increased expression of these factors may explain the undifferentiated, self-renewing state of brain cells and de-regulated cell-cycle signaling pathways that support cellular proliferation in glioma and GBM [236]. Zhang et al. in his study showed that brain-enriched miRNA-128 was also down regulated in glioma tissues and cell-lines and overexpression of miRNA-128 inhibited cellular proliferation through negatively regulating E2F3a, which is highly expressed in glioma and important for cell cycle progression (Figure 2) [58]. Papagiannakopoulos et al. recently showed that miRNA-128 represses growth and enhances neuronal differentiation of glioma-initiating neural stem cells (gNSCs) by downregulating onco- genic receptor tyrosine kinases (RTKs), epithelial growth factor receptor (EGFR) and platelet-derived growth factor receptor-α (PDGFRα) (Figure 2) [59]. In an independent study, Godlewski et al., reported that overexpression of miRNA-128 reduces glioma cell proliferation by downregulating Bmi-1 (B lymphoma mouse Moloney leukemia virus insertion region 1), decrease in histone methylation.

**Figure 2 Roles of miRNA-128 in different cellular processes:** The role of miRNA-128 in the different biological processes and multistep events that lead to cancer are shown. The experimentally validated target genes of miRNA-128 are depicted along with the respective biological processes.
(H3K27me3) and Akt phosphorylation and up-regulation of p21CIP1 levels [60]. As Bmi-1 is also known to promote the stem cell renewal, a process that is important in glioma, hence miRNA-128 may be used against the “stem cell-like” characteristics of glioma cells [237]. These data suggest that miRNA-128 may suppress cancer pathogenesis by inducing differentiation out of a stem cell-like state. Roth et al. recently reported upregulation of miRNA-128 in the blood samples of glioblastoma patients compared to healthy controls and speculated that this miRNA fingerprint may be used as suitable biomarker for glioblastoma [238].

Besides these, levels of miRNA-128 have been reported to be deregulated in autism, prion-induced neurodegeneration, Huntington disease, Parkinson disease and Alzheimer disease [239-242]. Several evidences in the literature show that under different biological conditions, expression patterns of miRNA-128 varies i.e. in some instances, it is up regulated whereas in some, it is down regulated (Table 3). Furthermore, Eletto et al. in his study showed that miRNA-128a inhibits expression of the pre-synaptic protein SNAP25 by binding to its 3′UTR (Figure 2). They observed Tat mediated deregulation of miRNA-128, in primary cortical neurons during the infection of neurons by HIV-1. However, the role of miRNA-128a in regulating synaptic activity in normal and in neurodegenerative disorders including HIV-1 Encephalopathy (HIVE) needs to be determined [61].

**Expression of pro-neural miRNA-128 in cancers other than brain**

Cancer occurs due to accumulation of several genomic alterations and is characterized by unrestricted proliferation, invasion, and metastasis. miRNAs normally negatively regulate their transcript targets and recent evidence indicates that miRNAs may function as tumor suppressors (by binding to oncogenes and suppressing them) or oncogenes (by binding to tumor suppressor genes and suppressing them) and alterations in miRNA expression may play a critical role in the cancer initiation and progression [255,256]. Within the past few years, profiling of the miRNome

| miRNA     | Disease                               | Status | Reference | Year |
|-----------|---------------------------------------|--------|-----------|------|
| hsa-miRNA-128a | Acute lymphoblastic leukemia (ALL) | u      | [244]     | 2007 |
| hsa-miRNA-128a | Acute myeloid leukemia (AML)         | d      | [244]     | 2007 |
| hsa-miRNA-128a | Alzheimer’s disease                   | u      | [242]     | 2007 |
| hsa-miRNA-128a | Autism spectrum disorder (ASD)       | u      | [239]     | 2008 |
| hsa-miRNA-128a | Glioblastoma                         | d      | [213]     | 2005 |
| hsa-miRNA-128a | Glioblastoma multiforme (GBM)        | d      | [95]      | 2008 |
| hsa-miRNA-128a | Malignant melanoma                   | d      | [245]     | 2008 |
| hsa-miRNA-128a | Oral Squamous Cell carcinoma (OSCC)  | d      | [246]     | 2008 |
| hsa-miRNA-128a | Pituitary adenoma                    | d      | [247]     | 2007 |
| hsa-miRNA-128a | Breast cancer                        | u      | [248]     | 2008 |
| hsa-miRNA-128b | Lung cancer                          | d      | [249]     | 2008 |
| hsa-miRNA-128b | Acute lymphoblastic leukemia (ALL)   | u      | [244]     | 2007 |
| hsa-miRNA-128b | Acute myeloid leukemia (AML)         | d      | [244]     | 2007 |
| hsa-miRNA-128b | Breast cancer                        | u      | [250]     | 2005 |
| hsa-miRNA-128b | Chronic pancreatitis                 | u      | [251]     | 2007 |
| hsa-miRNA-128b | Colorectal cancer                    | u      | [252]     | 2006 |
| hsa-miRNA-128b | Lung cancer                          | u      | [252]     | 2006 |
| hsa-miRNA-128b | Malignant melanoma                   | d      | [245]     | 2008 |
| hsa-miRNA-128b | Pancreatic cancer                    | u      | [252]     | 2006 |
| hsa-miRNA-128b | Hepatocellular carcinoma (HCC)       | u      | [253]     | 2009 |
| hsa-miRNA-128b | Acute promyelocytic leukemia (APL)   | d      | [254]     | 2009 |
| hsa-miRNA-128b | Glioma                               | d      | [58]      | 2008 |
| hsa-miRNA-128b | Neurodegeneration                    | u      | [240]     | 2008 |
| hsa-miRNA-128b | Neuroblastoma                        | d      | [55]      | 2009 |
| hsa-miRNA-128b | Huntington’s disease                 | d      | [241]     | 2010 |
(global miRNA expression levels) is common and abundant miRNome data are currently available for various cancers. MiRNA expression can be correlated with cancer type, stage, and other clinical variables which may be useful for the classification, diagnosis, or prognosis of some human malignancies [257]. With respect to miRNA-128, it is known that miRNA-128 may act as a tumor-suppressor. Kotani et al. in his study reported down regulation of miRNA-128 in MLL-AF4 Acute Lymphocytic Leukemia and Khan et al. revealed down regulation of miRNA-128 in invasive prostate cancer cells as compared to benign prostate epithelial cell lines, where its levels are elevated [254,258]. In addition, miRNA-128 was significantly reduced in chemoresistant breast tumor-initiating cells (BT-ICs) enriched from breast cancer cell lines and primary breast tumors (P < 0.01), accompanied by an overexpression of Bmi-1 and ABCCS5, which were identified as targets of miRNA-128 [259]. In contrast to these studies, strong induction of miRNA-128 has been observed in endometrial cancer [260] as well as in acute lymphoblastic leukemia (ALL) [244]. Up regulation of miRNA-128 not only suppressed the colony formation ability and invasiveness of pituitary tumor cells but also suppressed pituitary GH3 tumor growth in xenografts via, Bmi-1. MiRNA-128 found to regulate its direct target Bmi-1 and PTEN-AKT pathway in pituitary tumors [62]. Allelic loss in chromosome 3p (where miRNA-128-2 is present) has been shown to be associated with the most aggressive form of lung carcinogenesis. Furthermore, it was observed that loss of heterozygosity (LOH) of MicroRNA-128b in tumor samples correlated significantly with clinical response and survival following Gefitinib via EGFR [249]. Although the increase/decrease of miRNA-128 has been reported in a number of the studies related to cancer but it is not known whether it is a cause or effect of the disease.

Pro-neural miRNA-128 as regulator of apoptosis
Alterations in susceptibility to apoptosis is a key factor for the survival of a malignant cell [261] and it enhances resistance to conventional anticancer therapies [262]. As the altered expression of pro-neural miRNA-128 was found in several cancers, numerous studies were undertaken to delineate the mechanism for the inhibition of cell proliferation and induction of apoptosis by miRNA-128. Sean Lawler’s laboratory demonstrated that ectopic expression of miRNA-128 in human glioma neurosphere cultures (having stem-like properties) led to reduction in glioma neurosphere number and volume by down regulating Bmi-1 (Figure 2) [60]. In addition to this, several independent studies have illustrated the anti-proliferative role of miRNA-128 in glioma cells and glioblastoma cell lines [58,236]. Infact, ginsenoside Rh2, a triterpene saponin has also been found to inhibit glioma cell proliferation by up-regulating microRNA-128 [263]. Further, over expression of miRNA-128 leads to an alteration in the expression of genes implicated in cytoskeletal organization (via truncated isoform of NTRK3) as well as genes involved in apoptosis, cell survival and proliferation, including the anti-apoptotic factor BCL2 in SH-SY5Y neuroblasts cells [63]. In our laboratory also, we recently observed that miRNA-128 overexpression induced apoptosis by down regulation of Bax and up regulation of p53 and Bak [57]. Furthermore, transcriptome analysis of miRNA-128 overexpressed cells revealed that miRNA-128 inhibits SIRT1 expression directly through a miRNA-128 binding site within the 3’ UTR of SIRT1 (Figure 2). Finally, we found that miRNA-128 induces apoptosis in wild type (WT) p53 as well as in mutant p53-expressing cells in a p53-dependent and -independent manner via induction of PUMA in MCF7, MDA-MB-231, HCT116 p53 +/+ and HCT116 p53 −/− cells respectively [264]. In our study, we also demonstrated that miRNA-128 augments the antitumor effects of compounds (Etoposide and Cisplatin). Contrary to our findings, Yolanda’s group has shown that ectopic expression of miRNA-128 downregulated genes that induce apoptosis and upregulated genes implicated in cell survival [63]. In an another recent study, miRNA-128 was found to target Bax in breast cancer cell line MDA-MB-231 and downregulation of miRNA-128 sensitised MDA-MB-231 cells to chemodrugs [265]. Furthermore, Donzelli et al. observed that miRNA-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-Fluorouracil treatment via E2F5 (Figure 2) [266]. Based on the above information, we can say that depending upon the cell type; miRNA-128 can have anti-apoptotic as well as pro-apoptotic functions. It seems that miRNA-128 can be targeted to facilitate cancer cell death and/or inhibit cancer cell growth; however, this aspect warrants further investigation.

Role of miRNA-128 in cell motility, angiogenesis and senescence
Ability to migrate and eventually disseminate to distal sites is one of the key characteristic of tumor cells, which is also responsible for the relative aggressiveness of the tumor. Data from several independent studies showed that overexpression of miRNA-128 inhibits cell motility and invasiveness. Evangelisti et al. proved that overexpression of miRNA-128 reduces neuroblastoma cell motility and invasiveness by targeting Reelin and DCX (Figure 2) [55]. DCX is a microtubule-associated protein required for neuroblastic migration during cerebral cortex development [267] while Reelin is a high-molecular-weight secreted glycoprotein, which is thought to play its role as a guide for migratory neurons [268]. Messi et al. described DCX as a marker of SK-N-SH neuroblastoma cells that show high motility and invasiveness [269]. DCX expression is also
detectable in some tumors of the nervous system, such as GBM and neuroblastoma. Reelin has been shown to be a positive marker for prostate carcinoma aggressiveness [270] and is overexpressed in retinoblastoma and esophageal carcinoma and its expression is directly correlated with tumor aggressiveness [271,272]. Khan et al. investigated the proteomic alterations in a cohort of 15 prostate-derived tissues from adjacent benign prostate (Benign), clinically localized prostate cancer (PCA) and metastatic disease from distant sites (Mets). By coupling multidimensional protein fractionation and quantitative mass spectrometry with bioinformatics-based enrichment analysis, they demonstrated the involvement of miRNA-128 in the stages of prostate cancer progression. They have shown using qRT-PCR that miRNA-128 levels were reduced in invasive prostate cancer cells as compared to benign prostate epithelial cell lines. Further, over expression of miRNA-128 attenuated invasion in prostate cancer cells while its knockdown induced invasion in benign prostate epithelial cells as revealed by matrigel invasion assay [258]. These findings suggest that miRNA-128 reduces cell motility and invasiveness of tumor cells and thus prevents angiogenesis. In an independent study, Shi et al. observed that overexpression of miRNA-128 attenuated invasion in prostate cancer cells while its knockdown induced invasion in benign prostate epithelial cells as revealed by matrigel invasion assay [258]. These findings suggest that miRNA-128 reduces cell motility and invasiveness of tumor cells and thus prevents angiogenesis.

In an independent study, Shi et al. observed that miRNA-128 overexpression inhibited tumorigenesis and angiogenesis through targeting p70S6K1 and suppressing downstream molecules of p70S6K1 such as HIF-1 and VEGF [273]. Their study identified a link between miRNA-128 and p70S6K1 axis, which plays a vital role in glioma angiogenesis (Figure 2). We provided the first evidence of miRNA-128-2 to be a new regulator of cholesterol homeostasis [277]. Our in vitro results present a novel opportunity to investigate microRNA related interactions invivo and their role in cholesterol regulation. We believe validation using invivo model should not only provide novel insights into understanding of cholesterol regulation by miRNAs but should also help us to combat a variety of cholesterol related pathologies.

### Insights into regulation of cholesterol metabolism by miRNA-128: a new key player in cholesterol related disorders

Aberrant regulation of cholesterol homeostasis is associated with obesity as well as multiple types of cancer. The regulation of cholesterol homeostasis pathways is complex with transcriptional regulation by sterol-regulatory element-binding protein (SREBP) and liver X receptor/retinoid X receptor (RXR) transcription factors but poorly understood at the post-transcriptional levels [275,276]. While investigating the mechanism of miRNA-128 induced apoptosis, we observed that besides regulating the genes of apoptosis, miRNA-128 also regulates cholesterol metabolism and fatty acid biosynthesis pathways. In our study, we discovered that miRNA-128 up-regulated cholesterol synthesis genes and down regulated fatty acid biosynthesis genes. miRNA-128 further affected cholesterol efflux pathway by direct targeting ABCA1, ABCG1 and RXRα (Figure 2).

Over expression of Bmi-1 oncogene has been found to promote NSC self-renewal by repressing the p16^ink4a and p19^Arf senescence pathways [274]. As miRNA-128 directly targets Bmi-1 oncogene, the role of miRNA-128 in senescence is also evident. Observation by Venkata-raman’s group of increased methylation of histone 3 lysine 9 (H3K9me2) (a mark of repressed gene expression mediated by the Bmi-1 polycomb repressor complex) after overexpression of miRNA-128 further confirms the role of miRNA-128 in promoting cellular senescence. They also observed that overexpression of miRNA-128a in medulloblastoma alters the intracellular redox state of the tumor cells. In our study also, over expression of miRNA-128 in HEK293T cells led to an increase in reactive oxygen species [57]. This is quite interesting for therapeutic scenario where miRNA-128 can be used as therapeutic modality for treating cancer, as cancer stem cells are more resistant to therapy due to a lower overall redox state, where it can induce ROS [235].

### Biological relevance of miRNA-128 as revealed by bioinformatic analysis

The overall cellular functions and pathways affected by this miRNA remains still undiscovered due to lack of high throughput target validation methods. To reveal biological significance of miRNA-128, a list of predicted targets of miRNA-128 was made using the miRNA target prediction software, TargetScan 5 program (Table 4) [278]. From this list, we discovered that 90 targets of miRNA-128 were conserved among 9 species (Human, Mouse, Chimpanzee, Rhesus, Cow, Chicken, Frog, Rat, Opossum); thereby indicating possible mechanistically conserved functions of this miRNA (Figure 3). To evaluate the specific pathways or processes that are targeted by miRNA-128, we used the list of these ninety conserved targets to find enriched pathways by the PANTHER and GeneCodis [279,280] analysis. Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade, TGF-beta signaling pathway, Angiogenesis, Insulin/IGF pathway-protein kinase B signaling cascade, PI3 kinase pathway, Wnt signaling pathway were found to be the most enriched biological pathways as revealed by the PANTHER analysis (Figure 4).

Interestingly, we observed that the Insulin signaling pathway and chemokine signaling pathway were the enriched categories (p-value < 0.05) in both PANTHER and GeneCodis analysis. Till now, only one study by Motohashi et al. describes about the regulation of Insulin signaling pathways by miRNA-128a through the regulation of INSNR (insulin receptor), IRS1 (insulin receptor substrate 1) and PIK3R1 (phosphatidylinositol 3-kinases regulatory 1) [281]. There are a few reports which have talked about the involvement of
miRNA-128 in TGF-β signaling [282] and PI3 kinase pathway [60]. The reports which have revealed the association between miRNA-128 and angiogenesis, have been described by us in the above section. However, regulation of Wnt signaling and chemokine signaling pathways by miRNA-128 needs further validation. Surprisingly, metabolic process came out to be the highest rated biological process with maximum number of genes during PANTHER Analysis (Figure 5). Our recent work on the regulation of cholesterol metabolism by miRNA-128 point towards a possible link between miRNA-128 and metabolic processes which is just beginning to be revealed and certainly merits further studies. Such discoveries not only provide new insights into mode of action of miRNA-128, but also raise hopes for translating miRNA-128 for therapy.

Future directions/conclusions

MiRNA-128 is encoded by two distinct genes, viz., R3HDM1 and ARPP21. Interestingly, insilico analysis of transcription factor binding sites of these two genes reveals almost similar pattern of transcription factors (unpublished data). This suggests that these two genes may presumably resulted from a gene duplication event. Until now, neither transcription factors binding proteins of hsa-miRNA-128 gene nor epigenetic factors, have been identified that interact with the regulatory region of this miRNA. However, Monteys et al. have recently suggested dual regulation of miRNA-128-2 by both intronic (pol III) and host gene (Pol II) promoters in acute

### Table 4 List of ninety conserved targets of miRNA-128 among nine species

| C1orf144 | FOXP2 | RELN | ARFGEF1 |
|----------|-------|------|---------|
| AFF4     | COR1T1| ENAH | C5orf41 |
| EYA4     | WSB1  | hCG_1757335 | JMD1C |
| PLK2     | PLAG1 | IRS1 | NDUF54  |
| ONECUT2  | NRP2  | RNF38| UPF1    |
| RYBP     | HAPLN1| PDE7B| SPRY2   |
| SOCS6    | CDH11 | MAPK14| ELL2    |
| UBR5     | ZHX1  | UBE2N| DLL4    |
| LBH      | STK39 | MED13| MLL3    |
| C6orf60  | PSD5B | GRIA3| MEIS2   |
| SYT1     | SEMA6A| RAP1B| SPOPL   |
| BAZZ1B   | ZNF827| UBE2W| RAPGEF2 |
| APBA2    | FLRT3 | ZNF618| MARCKS  |
| ISL1     | KLF4  | TMEFF1| ARID2   |
| UNC13C   | DNAJC13| tcag7.1228| ZFH4X4 |
| FRYL     | SERTAD2| AFF3 | CPEB3   |
| C5orf13  | INSM1 | CITED2| TME189-U2E2V1 |
| WNK1     | SATB2 | NARG1| UBE2V1  |
| FBXO33   | HOXA10 | TSC1 | CPEB4   |
| TNPO1    | OTX2  | MED14| EN2     |
| ABL2     | APPBP2| FUBP3| PDE3B   |
| PPP1CC   | PEL2  | NIPBL| MAN2A1  |
| ARID1B   | ATP2B1 |       |         |

Figure 3 Strategy for filtering common genes among nine species: Total targets of miRNA-128 have been extracted using TargetScan 5 program for nine species (Human, Mouse, Chimpanzee, Rhesus, Cow, Chicken, Frog, Rat, Opossum). Data was arranged in a tabular format where the union of all genes from the mentioned species were represented as first column in each row (row head). The subsequent columns in first row had species names in them (column head). For every gene, 1 was written under the species where it was found to be present and zero otherwise. This way, a matrix of 1 and zeroes was populated for every gene where 1 means presence and zero means absence. In the last column, sum across the row was taken to count the number of species in which a particular gene was present. We chose only those genes with presence in all nine species. This led to a list of ninety genes which we called high confidence set and were conserved among these species. The total green area specifies ninety common targets whereas red specifies the absence of a particular target in a particular species out of nine species.
lymphoblastic leukemia [283]. The fact that miRNA-128 plays multiple roles - a pro-apoptotic molecule, an anti-apoptotic molecule as well as a regulator of cholesterol homeostasis, raise the possibility of exploiting miRNA-128 for therapeutic intervention and development of novel therapies. Further, therapeutic modalities either using replacement strategy by miRNA-128 mimetics (for upregulation of miRNA-128) or using antisense miRNA oligonucleotides (AMOs or antagonims), LNAs (Locked nucleic Acid) (for downregulation) may now be pursued

Figure 4 Biological relevance of miRNA-128 as revealed by bioinformatic analysis: The biological pathways affected by miRNA-128 were revealed by the PANTHER and Gene Codis analysis using the list of common ninety targets as input. Insulin signalling pathway and chemokine signaling pathway were the enriched categories in both PANTHER and GeneCodis analysis (p-value < 0.05).

Figure 5 GO biological processes by PANTHER analysis: The highest rated biological process being affected by miRNA-128 came out to be metabolic process with maximum number of genes during PANTHER analysis.
in an effort to target a particular disease. We believe that there are several fundamental questions that still need to be answered and are open for investigation which will help in the development of miRNA-128 as therapeutics.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

YKA and NS conceived the study. The survey of the literature and the inferences were made by YKA and NS. The bioinformatics analysis was carried out by YKA. The manuscript was drafted by YKA and NS. Both authors have read and approved the final manuscript.

**Acknowledgements**

The authors acknowledge the Council of Scientific and Industrial Research (CSIR) funded project. Genomic dynamics in cellular organization, differentiation and enantiospecificity (GENCODE-C, BSC-0123). YKA was supported with RA Fellowship from BSC-0123. We also acknowledge Dr. Amit Kumar Yadav for their help.

Received: 26 September 2013 Accepted: 12 February 2014

**References**

1. Lee RG, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843–854.
2. Wightman B, Ha I, Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75:855–862.
3. Slack FJ, Barron M, Liu Z, Ambros V, Horvitz HR, Ruvkun G: The lin-41 RBCC gene acts in the C. elegans heterochrony pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell 2000, 5:559–669.
4. Abrahante JE, Daul AI, Li M, Volk ML, Tennesien JM, Miller EA, Rougvie AE: The Caenorhabditis elegans hunchback-like gene lin-37/NFL-1 controls developmental timing and is regulated by microRNAs. Dev Cell 2003, 4:625–637.
5. Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ: The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell 2005, 8:321–330.
6. Karp X, Ambros V: Developmental biology. Encountering microRNAs in cell fate signaling. Science 2005, 310:1288–1289.
7. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83–86.
8. Stadler BM, Ruhola-Baker H: Small RNAs: keeping stem cells in line. Cell 2008, 132:563–566.
9. Yi R, Poy MN, Stoffel M, Fuchs E: A skin microRNA promotes differentiation by repressing stemness. Nature 2008, 452:225–229.
10. Chang AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1200–1297.
11. Lu S, Sun YH, Shi R, Clark C, Li L, Chiang VL: Novel and mechanical stress-responsive MicroRNAs in Populus trichocarpa that are absent from Arabidopsis. Plant Cell 2005, 17:2186–2203.
12. Lynam-Lennon N, Maher SG, Reynolds JV: The roles of microRNA in cancer and apoptosis. Biof Rev Chromatogr Soc 2009, 8455–71.
13. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005, 122:6–7.
14. Li C, Yang WV, Lee S, Xu J, Ma S, Xi H, Seitz H, Horwich MD, Syrzycka M, Honda BM, Kitterl EL, Zapp ML, Katterhoff CF, Schulz N, Theraufkau WE, Weng Z, Zarev PD: Collapse of germline miRNAs in the absence of Argonaute3 reveals somatic piRNAs in flies. Cell 2009, 137:509–521.
15. Latronico MV, Catalucci D, Condorelli G: Emerging role of microRNAs in cardiovascular disease. Circ Res 2007, 101:1225–1236.
16. Hansen T, Olsen L, Lindow M, Jakobsen KO, Ullum H, Jonsson E, Andreassen OA, Djurovic S, Melle I, Agartz I, Hall H, Timm S, Wang AG, Werge T: Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2007, 2:e4873.
17. Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheuvinus A, Ståhle M, Piccirilli A: MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007, 2:e610.
18. Williams MD, Mitchell GW: MicroRNAs in insulin resistance and obesity. Exp Diabetes Res 2012, 2012:649696.
19. Murakami Y, Yasuda T, Saigo K, Usukura T, Toyoda H, Okano T, Shimotohno K: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537–2545.
20. Hanrlman M, Scaria V, Pillaia B, Brahmacari SK: Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 2005, 337:1214–1218.
21. Weiler J, Hunziker J, Hall J: Anti-miRNA oligonucleotides (AMOs): amplification to target miRNAs implicated in human disease? Gene Ther 2006, 13:496–502.
22. Rogers K, Chen X: Biogenesis, turnover, and mode of action of plant MicroRNAs. Plant Cell 2013, 25:2383–2399.
23. Pillaia RS, Bhattacharyya SN, Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007, 17:18–26.
24. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215–233.
25. Wu W, Sun M, Zou GM, Chen J: MicroRNA and cancer: current status and prospective. Int J Cancer 2007, 120:953–960.
26. Kozomara A, Griffiths-Jones S: miBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011, 39:D152–D157.
27. Peterson KL, Dentrich MR, McPeek MA: MicroRNAs and metazoan macroevolution: insights into canalization, complexity, and the Cambrian explosion. Biosci 2009, 31:736–747.
28. O’Carroll D, Schaerfer A: General principals of miRNA biogenesis and regulation in the brain. Neuropsychopharmacology 2013, 38:39–54.
29. Motti D, Bixby JL, Lemmon VP: MicroRNAs and neuronal development. Semin Fetal Neonatal Med 2012, 17:347–352.
30. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res 2004, 14:1902–1910.
31. Griffiths-Jones S: Annotating noncoding RNA genes. Annu Rev Genomics Hum Genet 2007, 8:279–298.
32. UI Hussain M: Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action. Cell Tissue Res 2012, 349:405–413.
33. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN: The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415–419.
34. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN: The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004, 18:3016–3027.
35. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Couch N, Shiekhattar R: The Microprocessor complex mediates the generation of microRNAs. Nature 2004, 429:323–324.
36. Kim YK, Kim VN: Processing of intrinsic microRNA. EMBO J 2007, 26:775–783.
37. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC: The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell 2007, 130:89–100.
38. Lund E, Gutttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of microRNA precursors. Science 2004, 303:95–98.
39. Cheloufi S, Dos Santos CO, Chong MW, Hannon GJ: A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010, 465:584–589.
40. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, Lawson ND, Wolfe SA, Giraudel A: A novel microRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010, 329:1694–1698.
41. Yates LA, Notbury CJ, Gilbert RJ: The long and short of microRNA. Cell 2013, 153:516–519.
42. Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11:597–607.
43. Mestler G, Toschi T: Mechanisms of gene silencing by double-stranded RNA. Nat Rev 2004, 431:343–349.
44. Drom UA, Nielsen FC, Lund AH: MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 30:460–471.
45. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I: MicroRNAs to Nanog. Ooct and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124–1128.
46. Liu J: Control of protein synthesis and mRNA degradation by microRNAs. Cell 2008, 135:214–221.

47. Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835–840.

48. Salmena L, Poliseno L, Tay J, L. Kataoka S, L. Visvader J, S. Bantle J, T. Pilscher M, T. Rice A, S. Rice A: miRNAs in development and pathogenesis of nervous system. Science 2013, 340:1344–357.

49. Fineberg SK, Kiskos KS, Davidson BL: MicroRNAs potentiate neural development. Nat Neurosci 2009, 64:303–309.

50. Nowak JS, Michlewski G: miRNAs in development and pathogenesis of the nervous system. Biochim Biophys Acta 2013, 1815:815–820.

51. Sempere LF, Freemantle S, Pitá-Royle I, Moss E, Dmitrovsky E, Ambros V: Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004, 5:R13.

52. Rosenzweig B, S apprentices L, Koch P, Brudno O, Bortolomei L. Pluripotent stem cell-derived somatic stem cells as tool to study the role of microRNAs in early human neural development. Curr Opin Mol Biol 2013, 13:707–722.

53. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim HD: Impacts of cancer stemness and cancer stemness to glioma cells by degrading micro-RNA-mediated suppression of Sox2. Cancer Res 2011, 71:3410–3421.

54. Evangeli D, Michalis M, Marinos D, Giannis G, Galarraga S, Buh M, Magdalinos S, McDowell HP, Messi E, Gulino A, Formaggia MG, Ciafre SA: MEK3 promoter methylation and invasiveness. PNAS 2009, 106:4276–4287.

55. Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, Maire P, Price R, Nakano I, Price R, Nakano I, Price R, Nakano I, Price R, Nakano I, Price R, Nakano I: Tissue-specific control of brain-enriched miR-7 biogenesis. Genes Dev 2013, 27:24–38.

56. Okuda H, Xing F, Panzetta P, Sharma S, Watabe M, Pai SK, Mo YY, Xing F, Panzetta P, Sharma S, Watabe M, Pai SK, Mo YY, Xing F, Panzetta P, Sharma S, Watabe M, Pai SK, Mo YY: Control independent regulation of the tumor suppressor PTEN by competing endogenous miRNAs. Cell 2011, 147:344–357.

57. Finelli A, Romeo S, Maciotta S, Pfefferle S: Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004, 5:R13.

58. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Parmiani G, Melino G, Vasa-Nicotera M, Vasa-Nicotera M, Vasa-Nicotera M, Vasa-Nicotera M, Vasa-Nicotera M, Vasa-Nicotera M: miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neuromitochondria in vitro. Biochem Biophys Res Commun 2010, 394:921–926.

59. Kefas B, Godlewski J, Comeau L, Li Y, Bos A, Bos A, Bos A, Bos A, Bos A, Bos A, Bos A, Bos A, Bos A, Bos A: MicroRNA-7 inhibits the epithelial growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008, 68:3565–3572.

60. Edsinger D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Battery MM, Tada T, Dolan BM, Sharp PA, Sheng M: Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010, 63:373–385.

61. Wang G, Mao W, Zheng S, Ye J: Epidermal growth factor receptor-regulated miR-125a is a metastatic inhibitor of lung cancer. FERs 2009, 185:214–227.

62. Boissart C, Nissan X, Giraud-Triboult K, Peschanski M, Benchoua A: MicroRNA-132 dysregulation in schizophrenia has implications for both of neuronal function and plasticity. Biochem J 2013, 457:103–113.

63. Siegel C, Li L, Liu F, Benashski SE, McCullough LD: miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to安倍 differences in the response to cerebral ischemia. Proc Natl Acad Sci U S A 2011, 108:1652–1657.

64. Wanet A, Tacheny A, Arnold T, Renard P: miR-212 regulates cell-to-cell interactions and functions: within and beyond the neuronal compartment. Nucleic Acids Res 2012, 40:4742–4753.

65. Klein ME, Lioy DT, Ma L, Impy S, Mandel G, Goodman RH: Homestatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007, 10:1513–1514.

66. Smith PV, Delay C, Garz D, Papon MA, Plane E, Serjeant N, Buée L, Hebbert SS: MicroRNA-132 is loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 2011, 20:4016–4024.

67. Fromm J, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H: MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 2009, 31:965–973.

68. Miller BH, Zier Z, L. Lanz TA, Deng S, Strehlmann M, Willougby D, Penny JJ, Elsworth JD, Lawrence MS, Roth RH: Edsinger D, Kemi R, Wahnstedt C: MicroRNA-132 dysregulation in schizophrenia has implications for both of neurodevelopment and adult brain function. Proc Natl Acad Sci U S A 2012, 109:3125–3130.

69. Tognini P, Pizzorusso T: MicroRNA212/132 family: molecular transducer of neuronal function and plasticity. J Biol Chem 2012, 4465:510–515.

70. Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH: Impy S: An activity-regulated microRNA controls dendritic plasticity by down-regulating p25GAP. Proc Natl Acad Sci U S A 2008, 105:9093–9098.

71. Clovis YM, Enard W, Marinaro F, Hutter WB, De Pieltonei D: Convergent repression of Foxp2 and Foxp3 by miR-9 and miR-132 in embryonic mouse.
neocortex: implications for radial migration of neurons. Development 2012, 139:3322–3342.
8. Lages E, Gutin A, El Attif M, Ramus C, Ipaš I, Dupre L, Rolland D, salon C, Godfraind C, de Frainmont P. MicroRNA and target protein patterns reveal physiological features of glioma subtype. Proc Natl Acad Sci USA 2011, 108:20600.
9. Scott Hl, Tamaginri N, Narduzzo KE, Howarth JN, Lee YB, Wong LF, Brown Mw, Waterworth EC, Bashir Zl, Uney Jb. MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex. Eur J Neurosci 2012, 36:2941–2948.
10. Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, Alford A, Waters Mw. MicroRNA-132 regulates nutritional stress-induced chemokine production through repression of Sirt1. Mol Endocrinol 2009, 23:1876–1884.
11. Huang X, Lee Y, Zhang H, Hou L, Zhang M, Dayton Al. MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood 2011, 118:6793–6802.
12. Godoy J, Nishimura M, Webster Nj. Gondotropin-releasing hormone induces mir-132 and mir-212 to regulate cellular morphology and migration in immortalized LbetaT2 pituitary gonadotrope cells. Mol Endocrinol 2011, 25:810–820.
13. Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, Kwon E, Wang W, Tsai LH. Molecular Cancer 2014, 13:395–408.
14. Li KK, Yang L, Pang JC, Chan AK, Zhou L, Mao Y, Wang Y, Lau KM, Poon WS, Chong HY. miR-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet 2011, 20:731–751.
15. Wright C, Turner JA, Calhoun Vd, Perrone-Bizzozero N. Potential Impact of miR-132 and Its Targets in Schizophrenia. Front Genet 2013, 4:458.
16. Silber J, Lim Da, Petritsch C, Persson Al, Maunakea Ak, YU M, Vandenbemd Sr, Ginzgner Dg, James Cd, Costello Jf, Bergers G, Weiss Wa, Alvarez-Buyaña A, Hodgson Jg. miR-124 and miR-132 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008, 6:114.
17. Smt Rk, Szuhalki Kc, Pfeffer Rl, Li X, Guo W, Pathania M, Teng Qz, Luo Y, Peng J, Borey J, Jin P, Zhao X. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 2010, 28:1060–1070.
18. Kwon E, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C, Jiang C. miR-132 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 2012, 48:3234–3243.
19. Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C, Jiang C. miR-132 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 2012, 48:3234–3243.
20. Sun G, Ye P, Murali K, Lang X, Li Y, Li Y, Li Y, Wang A, Ma X, Shi Y. miR-137 forms a regulatory loop with nuclear receptor TLX in the developing mammalian brain. Acta Neuropathol 2013, 126:345–360.
21. Willemens Mh, Valles A, Mastersbock M, Olde Loohuis N, Kos A, Wissink-Lindhout Wm, De Brouwer Ap, Nillesen Wm, Pfundt R, Holder-Espiner C, van Bokhoven H, Aschrafi A, Kleefstra T. Genet Med 2013, 15:763–767.
22. Yermanos A, Wren N, Moore Dj, Achim Cl. Modulation of BK Channel by MicroRNA-9 in Neurons After Exposure to HIV and Methamphetamine. J Neuroimmune Pharmacol 2013, 8(5):1210–1223.
23. Tan Sl, Ohtsuka T, Gonzalez A, Kageyama R. MicroRNA9 regulates neuronal stem cell differentiation by controlling Hex1 expression dynamics in the developing CNS. Genes Cells 2012, 17:952–961.
24. Jung Hj, Coffinier C, Choe Y, Beigneux Ap, Davies Bs, Yang Sh, Barnes Rh 2nd, Hong J, Sun T, Pleasure Sj, Young Sg and Feng Lg. Regulation of pre-alamin A but not lamin B by miR-9, a brain-specific microRNA. Proc Natl Acad Sci U S A 2012, 109:E423–E431.
25. Makeyev Ev, Zhang J, Carrasco Ma, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007, 27:435–448.
26. Cheng Lc, Pastrana E, Tavaezoo M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci 2007, 10:1302–1309.
27. Lv Z, Yang L. MI-R124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol Med Rep 2013, 8:345–349.
28. Yoo As, Sun Ax, Li L, Scheglovitov A, Portmann T, Li Y, Lee-Messer C, Dowmetsch Re, Tsien Rw, Crabtree Gb. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 2011, 476:228–231.
29. Xiu Y, Cheung Wk, Ng Sg, Jiang X, Jiang S, Sze J, Leung Gk, Lu G, Chan Dt, Bao Xw, Kung Hf, Poos Ws, Li M. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012, 287:9962–9971.
30. Sober S, Laan M, Annillo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun 2010, 391:272–275.
31. Deng X, Ma L, Wu M, Zhang G, Jin C, Guo Y, Liu F. miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol 2013, 114:263–274.
32. Doeppeener Tr, Doehringer M, Bretschneider E, Zechariah A, Kaltbasser W, Muller J, Bocchi J, Bahr M, Herrmann Dm, Michel U. MicroRNA-124 protects against fetal cerebral ischemia via mechanisms involving Up1S4-dependent REST degradation. Acta Neuropathol 2013, 126:251–265.
33. Liu X, Li F, Zhao S, Luo Y, Kang J, Zhao H, Yan F, Su S, Al X. MicroRNA-124-mediated regulation of inhibitory member of apoptosis-stimulating protein of p53 family in experimental stroke. Stroke 2013, 44:1973–1980.
34. Dutta R, Chomayk Am, Chang A, Ribaudo Mv, Deckard Sa, Doud M, Edberg DD, Bai B, Li M, Baranini Se, Fox Rj, Staugaitis Sm, Macklin Wb, Trapp Bd. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurosci 2013, 7:657–665.
35. Yoo As, Staahll Bt, Chen L, Crabtree Gb. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 2009, 460:642–646.
36. Arvanitis Dn, Jungas T, Behar A, Davy A. Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124. Mol Cell Biol 2010, 30:2508–2517.
37. Vissanathan J, Lee S, Lee B, Lee Jw, Lee Sk. The microRNA miR-124 antagonizes the anti-nuclear REST/SC1 pathway during embryonic CNS development. Genes Dev 2007, 21:744–749.
38. Ponomarev Ed, Veremeyko T, Bartenova Ns. Visualization and quantitation of the expression of microRNAs and their target genes in neuroblastoma single cells using imaging cytometry. BMC Res Notes 2011, 4:517.
39. Silber J, Hashizume R, Pickard Sg, Kimura S, Zhang J, Berger Ms, Huse Jt, Vandenbemd Sr, James Cd, Hodgson Xg, Gupta N. Expression of miR-124 inhibits growth of medulloblastoma cells. Neur Oncol 2013, 15:833–840.
40. Lawson Sk, Dobrikova Ev, Shveygert M, Gromeier M. p38Alk1-mitogen activated protein kinase dephosphorylation and repression of signal transduction to translation machinery by miR-124 and –128 in neurons. Mol Cell Biol 2013, 33:127–135.
Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with Med Chem 2014, J Mol Neurosci Nature miR-134. A novel pathway regulates memory and plasticity via SIRT1 and 21: of cortical neuronal development by Mmu-miR-134. Modiano JF, Subramanian S: microRNA. Regulation of chemotropic guidance of nerve growth cones by ELMO/Dock180/Rac1 and Cdc42 signalling. EMBO J 2012, 31:2989–2921. Weng R, Cohen SM: Expression of BACE1/beta-secretase corre- lated with cell death in Alzheimer's disease. Toxicon Lett 2012, 209:94–105. Liu K, Liu Y, Mo W, Qiu R, Wang X, Hu J, He R: MiR-124 regulates early neurogenesis in the optic vesicle and forebrain, targeting NeuroD1. Nucleic Acids Res 2011, 39:2869–2879. Niu CS, Yang Y, Cheng CD: MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol 2013, 42:1533–1540. Schatt GM, Tueling F, Ngih EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME: A brain-specific microRNA regulates diencephalic spine development. Nature 2006, 439:283–289. Bicker S, Khudayarboev S, Weiss K, Zocher K, Baumeister S, Schatt G: The DEAH-box helicase DXH36 mediates denticulate localization of the neuronal precursor-microRNA-134. Genes Dev 2013, 27:991–996. Tay YM, Tam WL, Ang YS, Gaughwin PM, Yang H, Wang W, Liu R, George J, Ng HH, Perera RJ, Lufkin T, Rigopoulos I, Thomson AW, Lim B: MicroRNA-134 modulates the differentiation of mouse embryonic stem cells, where it causes post-transcriptional attenuation of Nanog and LHRH. Stem Cells 2008, 26:17–29. Li J, Wang Y, Luo J, Fu Z, Ying J, Yu W, Yu W: MiR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett 2012, 586:3761–3765. Ni J, Gao Y, Gong S, Guo S, Hisamitsu T, Jiang X: Regulation of mu-opioid type 1 receptors by microRNA134 in dorsal root ganglion neurons following peripheral inflammation. Eur J Pain 2013, 17:313–322. Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, Taniguchi Y, Burioka N, Ni J, Gao Y, Gong S, Guo S, Hisamitsu T, Jiang X: Nucleic Acids Res 2013, 39:94–1105. Shin D, Shin JY, McManus MT, Ptacek LJ, Fu YH: MicroRNA-mediated control of oligodendrocyte differentiation. Neuroreport 2010, 21:597–601. Shen H, Sun J, et al.: Downregulations of B-cell lymphoma 2 and mye- loid cell leukemia sequence 1 by microRNA 135c induce apoptosis in a glioblastoma cell line D8TRG-05MG. Int J Cancer 2010, 126:1029–1035. Xu Q, Sun Q, Zhang J, Li C, Chen W, Zhang Z: Downregulation of miR-135 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial carcinoma. Carcinogenesis 2013, 34:539–549. Rao SA, Arinjapammagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA, Somasundaram K: MiR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGRF in glioblastoma. PLoS One 2013, 8:e63164. Sarachana T, Zhou R, Chen G, Manji HK, Hu VW: Investigation of post- transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med 2010, 2:223. Zhao X, He X, Han X, Yu Y, Ye F, Chen Y, Hoang T, Xu X, Mi QG, Xin M, Wang F, Appel B, Lu QR: MicroRNA-mediated control of oligodendrocyte differentiation. Neuroreport 2010, 21:612–626. Dugas JC, Cuellar TL, Scholze A, Ibrahim A, Emery B, Zamanian JL, Foo LC, McManus MT, Barres BA: Dicer and miR-219 Are required for nor- mal oligodendrocyte differentiation and myelination. Neuroreport 2010, 21:597–601. Shin D, Shin JY, McManus MT, Packel LF, Fu YH: Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann Neurol 2009, 66:483–487. Kocerha J, Faghihi MA, Lopez-Toledano MA, Huang J, Ramsey AJ, Caron MG, Hammond SM, Bartel DP, Schier AF: The miR-135 family in colorectal cancer. Cancer Res 2008, 68:5802–5807. De Pietri TD, Pulvers JN, Haffner C, Murchison EP, Hannon GJ, Huttner WB: MicroRNAs are essential for survival and differentiation of newborn neurons. Development 2009, 136:3761–3769. Hammond SM, Bartel DP, Schier AF: MicroRNAs regulate brain morphogenesis in zebrasfish. Science 2005, 308:833–838. De Petro TD, Pulvers JN, Haffner C, Murchison EP, Hannon GJ, Huttner WB: MicroRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. Development 2008, 135:3911–3921. Huang T, Liu X, Huang M, Zhao X, Cheng L: miR-135 directly targets the Wnt1-cre-mediated conditional loss of Dicer results in malformation of the midbrain and cerebellum and failure of neural crest and dopaminergic differentiation in mice. J Mol Cell Biol 2010, 2:152–163. Schaefer A, O’Carroll D, Tan CL, Hifman D, Sugimori M, Llinas R, Greengard P: Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med 2007, 204:1553–1558.
171. Kawase-Koga Y, Low R, Otagai G, Pollock A, Deng H, Eisenhaber F, Maurer-Stroh S, Sun T: RNAi-Asl-III enzyme Dicer maintains signaling pathways for differentiation and survival in mouse cortical neural stem cells. J Cell Sci 2010, 123:586–594.

172. Bicker S, Schratt G: microRNAs: tiny regulators of synapse function in development and disease. J Cell Mol Med 2008, 12:466–476.

173. Fiore R, Siegel G, Schratt G: microRNA function in neuronal development, plasticity and disease. Biochim Biophys Acta 2008, 1779:471–478.

174. Stark KL, Xu Y, Bagchi A, Lai WS, Liu H, Hu R, Wan X, Pavlidis P, Mills AA, Karayorgou M, Gogos JA: Altered brain microRNA biogenesis contributes to phenotype deficits in a 22q11-deletion mouse model. Nat Genet 2008, 40:511–516.

175. Godlewski J, Newton HB, Chiocca EA, Lawler SE: Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 2011, 11:255–130.

176. Li Y, Xing H, Zhou CL, Han Y, Wang Y, Chen W, Chen J, Li J: MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells through the suppression of BCL2 and NF-kappaB1. Cancer Sci 2013, 104:529–534.

177. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG: MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol 2013, 15:1302–1316.

178. Li A, Lin X, Tan Y, Yin B, Han W, Zhao J, Yuan J, Qiang B, Peng X: Circadian gene Clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124. FEBS Lett 2013, 587:2455–2460.

179. He Z, Cen D, Luo X, Li D, Li P, Liang L, Meng Z: Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor. Med Oncol 2013, 30:557.

180. Peng B, Hu S, Jun Q, Luo D, Zhang X, Zhao H, Li D: MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma. Mol Cell Biochem 2013, 379:51–58.

181. Hou W, Yuntian L, Wensheng L, Chaofeng L, Harliyang H, Yueyang Y: MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS One 2013, 8:e54932.

182. Zhao S, Liu H, Liu Y, Wu J, Wang C, Hou X, Chen X, Yang Z, Zhao L, Che H, Bi Y, Wang H, Peng F, Ai J: miR-143 inhibits glycolysis and depletes steness of glioblastoma stem-like cells. Cancer Lett 2013, 332:253–260.

183. Chen L, Chen XR, Zhang R, Li P, Liu Y, Yan K, Jiang XD: MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. J Neurooncol 2013, 112:59–66.

184. Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B: Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas. Oncol Rep 2014, 29:1035–1041.

185. Yang TQ, Luo XJ, Wu TF, Ding DD, Zhao ZH, Chen GQ, Xie XS, Li B, Wei YX, Guo LC, Zhang Y, Huang YL, Zhou YX, Du ZW: miR-16 inhibits glioma cell growth and invasion through the suppression of BCL2 and NF-kappaB1. MPM-9 signaling pathway. Cancer Sci 2014 doi:10.1111/1349-7006.12726.

186. Zhang Y, Chen X, Lian H, Liu J, Zhou B, Han S, Peng B, Yin J, Liu W, He X: MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R. Oncol Rep 2013.

187. Chen Z, Li D, Cheng Q, Ma Z, Jiang B, Peng R, Chen R, Cao Y, Wan X: MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells by directly targeting PLD2. Mol Med Rep 2014, 9:503–508.

188. Wu Z, Wu Y, Tian Y, Sun X, Liu J, Ren H, Liang C, Song L, Hu H, Wang L, Jiao B: Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells. Oncol Lett 2013, 6:1447–1452.

189. Dai DW, Lu Q, Wang LX, Zhao WF, Cao YQ, Li YH, Han GS, Liu JM, He ZJ: Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 2013, 13:878.

190. Wang XR, Luo H, Li H, Cao L, Wang XF, Yan W, Wang YY, Zhang JX, Jiang T, Kang CS, Li N, You Y, Chinese Gloma Cooperative Group (CGGCG): Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-Ras, independently of PTEN. Neuro Oncol 2013, 15:1491–501.

191. Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, Yu C, Wu Z, Li J: miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun 2010, 402:135–140.

192. Glasgow SM, Laug D, Brawley VS, Zhang Z, Corder A, Yin Z, Wong ST, Li XN, Foster AE, Ahmed N, Deneen B: The miR-223/nuclear factor-κB axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci 2013, 33:13560–13569.

193. Li Z, Hu YY, Zhao J, Zhao YB, Sun JD, Yang YF, Ji CL, Liu ZB, Cao WD, Qu Y, Liu WP, Cheng G, Fei Z: MicroRNA-34a induces apoptosis in the human glioma cell line, A172, through enhanced ROS production and NOX2 expression. Biochem Biophys Res Commun 2014.

194. Rani SB, Rathod SS, Kanthik S, Kaur N, Muzumdar D, Shrias A: MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol 2013, 15:1302–1316.

195. Li SZ, Hu YY, Zhao J, Zhao YB, Sun JD, Yang YF, Ji CL, Liu ZB, Cao WD, Qu Y, Liu WP, Cheng G, Fei Z: MicroRNA-34a induces apoptosis in the human glioma cell line, A172, through enhanced ROS production and NOX2 expression. Biochem Biophys Res Commun 2014.
235. Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R: MicroRNA-128 (miRNA-128) down-regulation in glioblastoma targets ARPS (ANGPTL6), Bmi-1 and EZF-3a, key regulators of brain cell proliferation. J Neurooncol 2010, 98:297–304.

236. Fasano CA, Dimos JT, Ivanova NB, Lowry N, Lermisch IR, Temple S: shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell 2007, 1:57–59.

237. Roth P, Wichschenus J, Hoppold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A: A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neuroonem 2011, 118:449–457.

238. Abu-Elnuee K, Liu T, Gazzana FS, Nishimura Y, Wall DP, Geschwind DH, Lao K, Kosik KS: Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2009, 11:153–161.

239. Saba R, Goodman CD, Huzarewich RL, Robertson C, Booth SA: A miRNA signature of prion induced neurodegeneration. PLoS One 2008, 3:e3652.

240. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, Park KH, Jung KH, Lee SK, Kim M, Roh JK: Altered microRNA regulation in Huntington’s disease models. Exp Neurol 2011, 227:172–179.

241. Lok萎 W: MicroRNA speciation in fetus, adult and Alzheimer’s disease hippocampus. Neuroreport 2007, 18:297–300.

242. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y: miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009, 37:298–304.

243. Li Y, Sun L, Li Z, Zhang H, Nelly MB, Wang Y, Qian J, Jin Z, Zhang Y, Bohländer SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J: MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:19971–19976.

244. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008, 18:549–557.

245. Kozaki K, Imoto I, Miagi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008, 68:2094–2105.

246. Bottoni A, Zatelli MC, Ferracin M, Tagliaferi F, Piccin D, Vignali C, Calin GA, Negriani M, Croce CM, Degli Uberti EC: Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol 2007, 210:370–377.

247. Foekens JA, Suewerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Waanders E, Mattens JW: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2008, 105:13021–13026.

248. Weiss GI, Berns LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA: EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008, 19:1053–1059.

249. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbrì M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negriani M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Proc Natl Acad Sci U S A 2005, 102:13983–13988.

250. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901–1908.

251. Volinia S, Calin GA, Liu CG, Ambros V, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Paez J, Yanaihara N, Lanza G, Scapar A, Vecchione A, Negriani M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257–2261.

252. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, Zeng WT, Cao LQ, Tan HK, Su Q: Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-33B is downregulated. Hepatol Res 2009, 39:726–734.

253. Kotani A, Ha D, Hishe J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF: miR-128B is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009, 114:4169–4178.

254. Esquela-Kerscher A, Slack FJ: Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259–269.
256. Sevignani C, Calin GA, Siracusa LD, Croce CM: Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 2006, 17:189–202.

257. Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7930–7934.

258. Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R, Kalyana-Sundaram S, Michalakis G, Nesvizhskii AI, Ommen GS, Chinayani AM, Seekarkar A: Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 2010, 9:296–312.

259. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E: Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCG1. Clin Cancer Res 2011, 17:7105–7115.

260. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ: A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome. J Med Genet 2009, 46:433–439.

261. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309–1312.

262. Shi ZM, Wang J, Yan Z, You Y, Sun G, Hu J, Sun H: Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax. Cell Biol Int 2013, 37:653–658.

263. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioli F, Muti P, Strano S, Bandino G: MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012, 19:1038–1048.

264. Des Portes V, Pinard JM, Billuart P, Vinet MC, Koulakoff A, Carrie A, Gelot A, Des Portes V, Pinard JM, Billuart P, Vinet MC, Koulakoff A, Carrie A, Gelot A: Human embryonic and neuronal stem cell markers in retinoblastoma. Human Pathol 2007, 38:2129–2141.

265. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F: The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 2010, 124:89–99.

266. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F, Blandino G: The role of microRNA-128 in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 2010, 124:89–99.

267. Messi E, Florian MC, Caccia C, Zanisi M, Maggi R: Retinoic acid reduces human embryoblastoma cell migration and invasiveness: effects on DCX, L1ST1, neurofilaments-68 and vimentin expression. BMC Cancer 2008, 8:30.

268. Perrone G, Vincenzi B, Zagni M, Santini D, Panerelli R, Fiammiglia G, Verzi A, Leopardo D, Morini S, Russo A, Bazan V, Tomasini RM, Morello V, Tonini G, Rabotti C: Reelin expression in human prostate cancer: a marker of tumour aggressiveness based on correlation with grade. J Pathol 2007, 204:341–351.

269. Segel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F: Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007, 13:823–832.

270. Wang Q, Wu J, Wang X, Cheng L, Hu G, Sun Y, Zhang X, Wu M, Liu Z: CASK and its target gene Reelin were co-upregulated in human esophageal carcinoma. Cancer Lett 2002, 179:71–77.

271. Shi ZM, Wang J, Yan Z, You Y, Li CY, Qian X, Yin Y, Zhao P, Wang YY, Wang XF, Li MN, Liu LZ, Liu N, Jiang B: MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 2012, 7:e32709.

272. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R: Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005, 19:1432–1437.

273. Horton JD, Goldstein JL, Brown MS: SREBP: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125–1131.

274. Beavan SW, Tontozon P: Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006, 57:313–329.

275. Adlakha YK, Khanna S, Singh R, Singh VP, Agrawal A, Saini N: Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRalpha expression and cholesterol homeostasis. Cell Death Dis 2013, 4:e780.

276. Grimson A, Farh KK, Johnston WK, Garnett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27:91–105.

277. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karbik B, Daverman R, Diemer K, Muruganujan A, Narechania A: PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003, 13:2129–2141.

278. Adlakha and Saini: Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Molecular Cancer 2014 13:33.